56 related articles for article (PubMed ID: 7946067)
1. Influence of a mutation in the transmembrane domain of the p185c-erbB2 oncogene-encoded protein studied by molecular dynamics simulations.
Garnier N; Genest D; Hebert E; Genest M
J Biomol Struct Dyn; 1994 Apr; 11(5):983-1002. PubMed ID: 7946067
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane peptides from tyrosine kinase receptor. Mutation-related behavior in a lipid bilayer investigated by molecular dynamics simulations.
Samna Soumana O; Aller P; Garnier N; Genest M
J Biomol Struct Dyn; 2005 Aug; 23(1):91-100. PubMed ID: 15918680
[TBL] [Abstract][Full Text] [Related]
3. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
Sajot N; Genest M
J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
[TBL] [Abstract][Full Text] [Related]
4. Detailed description of an alpha helix-->pi bulge transition detected by molecular dynamics simulations of the p185c-erbB2 V659G transmembrane domain.
Duneau JP; Genest D; Genest M
J Biomol Struct Dyn; 1996 Apr; 13(5):753-69. PubMed ID: 8723771
[TBL] [Abstract][Full Text] [Related]
5. Insight into signal transduction: structural alterations in transmembrane helices probed by multi-1 ns molecular dynamics simulations.
Duneau JP; Garnier N; Genest M
J Biomol Struct Dyn; 1997 Dec; 15(3):555-72. PubMed ID: 9440002
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations of the transmembrane domain of the oncogenic ErbB2 receptor dimer in a DMPC bilayer.
Garnier N; Crouzy S; Genest M
J Biomol Struct Dyn; 2003 Oct; 21(2):179-200. PubMed ID: 12956604
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
Brandt-Rauf PW; Rackovsky S; Pincus MR
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
[TBL] [Abstract][Full Text] [Related]
8. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu oncogene-encoded p185 protein.
Brandt-Rauf PW; Pincus MR; Chen JM
J Protein Chem; 1989 Dec; 8(6):749-56. PubMed ID: 2576207
[TBL] [Abstract][Full Text] [Related]
9. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
10. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
[TBL] [Abstract][Full Text] [Related]
12. Correlated motions and propagation of the effect of a local conformational change in the transmembrane helix of the c-erb B2 encoded protein and its V659E mutant, studied by molecular dynamics simulations.
Garnier N; Genest D; Genest M
Biophys Chem; 1996 Feb; 58(3):225-37. PubMed ID: 8820408
[TBL] [Abstract][Full Text] [Related]
13. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.
Chen LI; Webster MK; Meyer AN; Donoghue DJ
J Cell Biol; 1997 May; 137(3):619-31. PubMed ID: 9151669
[TBL] [Abstract][Full Text] [Related]
14. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
15. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
16. A putative molecular-activation switch in the transmembrane domain of erbB2.
Fleishman SJ; Schlessinger J; Ben-Tal N
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15937-40. PubMed ID: 12461170
[TBL] [Abstract][Full Text] [Related]
17. Conformation of the transmembrane domain of the c-erbB-2 oncogene-encoded protein in its monomeric and dimeric states.
Brandt-Rauf PW; Pincus MR; Monaco R
J Protein Chem; 1995 Jan; 14(1):33-40. PubMed ID: 7779261
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of c-erbB2 receptor dimerization: coiled-coil structure of wild and oncogenic transmembrane domains--stabilization by interhelical hydrogen bonds in the oncogenic form.
Garnier N; Genest D; Duneau JP; Genest M
Biopolymers; 1997 Aug; 42(2):157-68. PubMed ID: 9234995
[TBL] [Abstract][Full Text] [Related]
19. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
20. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
